Keeley Teton Advisors LLC Purchases 1,487 Shares of Organon & Co. (NYSE:OGN)

Keeley Teton Advisors LLC lifted its position in Organon & Co. (NYSE:OGN) by 2.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,014 shares of the company’s stock after buying an additional 1,487 shares during the period. Keeley Teton Advisors LLC’s holdings in Organon & Co. were worth $1,053,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Lindbrook Capital LLC increased its holdings in Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after purchasing an additional 1,428 shares in the last quarter. Gladius Capital Management LP increased its holdings in Organon & Co. by 65.1% during the 4th quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock worth $31,000 after purchasing an additional 858 shares in the last quarter. GAMMA Investing LLC bought a new position in Organon & Co. during the 4th quarter worth about $38,000. Eagle Bay Advisors LLC increased its holdings in Organon & Co. by 100.0% during the 4th quarter. Eagle Bay Advisors LLC now owns 2,800 shares of the company’s stock worth $40,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Fidelis Capital Partners LLC bought a new position in Organon & Co. during the 1st quarter worth about $43,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

NYSE:OGN traded up $0.12 during mid-day trading on Friday, hitting $22.19. The stock had a trading volume of 987,601 shares, compared to its average volume of 1,395,104. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08. The stock has a market cap of $5.71 billion, a price-to-earnings ratio of 5.43, a PEG ratio of 1.02 and a beta of 0.85. The company’s 50 day simple moving average is $20.86 and its 200 day simple moving average is $19.03. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.31. The business had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. On average, equities research analysts forecast that Organon & Co. will post 4.29 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Monday, May 13th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, May 10th. This represents a $1.12 annualized dividend and a yield of 5.05%. Organon & Co.’s dividend payout ratio (DPR) is presently 27.38%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on OGN shares. The Goldman Sachs Group increased their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Piper Sandler increased their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.